Tekmira

The study is being conducted in Sierra Leone by the University of Oxford.

The new company will be focused entirely on hepatitis B, although officials previously said that Tekmira's other non-HBV RNAi programs would continue to advance.

The company also disclosed that it intends to continue working on its non-HBV RNAi drugs that have entered human testing, but was less clear about earlier-stage ones.

The news marks a key milestone for Tekmira, which announced earlier this month that it would merge with OnCore Biopharma to become an HBV-focused drug developer.

Following the transaction, hepatitis B will become Tekmira's top priority, although the company said it will continue work on its other RNAi programs.

The RNAi-based drug is designed to specifically target the strain of the virus responsible for the current outbreak.

Dicerna's new RNAi triggers and conjugate technology are entirely proprietary and fall outside of intellectual property held by other organizations, according to a company official.

NEW YORK (GenomeWeb) – Tekmira Pharmaceuticals may not be able to meet its year-end goal of providing US regulators with the data required to lift a hold on a Phase I trial of its investigational Ebola therapy TKM-Ebola, company officials disclosed last week.

NEW YORK (GenomeWeb) — October was a turbulent month on Wall Street for several key RNAi/microRNA players, with two companies — Regulus Therapeutics and Alnylam Pharmaceuticals — seeing major gains on encouraging clinical data and two others — Arrowhead Research and Tekmira Pharmaceuticals — taki

NEW YORK (GenomeWeb) — Tekmira Pharmaceuticals this week announced that it has started limited manufacturing of a new version of its siRNA Ebola treatment TKM-Ebola to specifically target the Guinea variant of the disease that is responsible for the current outbreak in Africa.

Pages

The ancestors of the Arizona bark scorpion and other scorpions and spiders underwent whole-genome duplication, KJZZ reports.

A cryptographic approach could help researchers keep genomic data private while researchers analyze it, Scientific American reports.

Andy Page, the former president of 23andMe, has joined a diabetes-management startup, according to CNBC.

In Cell this week: regulatory changes in pancreatic cancer, metabolic shifts in Alzheimer's disease, and more.